Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab
International Ophthalmology, 03/29/2012
Clinical Article
Gupta A et al. – Preoperative use of bevacizumab improved the 6–month visual outcome in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy and significantly reduced the occurrence of postoperative vitreous hemorrhage.



